Evaluation of the Efficacy of OSU-2S in the Treatment of Non-Small-Cell Lung Cancer and Screening of Potential Targets of Action

• Main Authors: Mengyuan Han (Author), Xiangran Liu (Author), Sendaer Hailati (Author), Nurbiya Nurahmat (Author), Dilihuma Dilimulati (Author), Alhar Baishan (Author), Alifeiye Aikebaier (Author), Wenting Zhou (Author)
• Format: Book
• Published: MDPI AG, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

(1) Background: OSU-2S is a derivative of FTY720 and exhibits significant inhibitory effects on various cancer cells. There is currently no research on the mechanism of the impact of OSU-2S on NSCLC development. We analysed and validated the hub genes and pharmacodynamic effects of OSU-2S to treat NSCLC. (2) Methods: The hub genes of OSU-2S for the treatment of NSCLC were screened in PharmMapper, genecard, and KM Plotter database by survival and expression analysis. The effect of OSU-2S on hub gene expression was verified by Western blot analysis. The ex vivo and in vivo efficacy of OSU-2S on tumour growth was verified using A549 cells and a xenografted animal model. (3) Results: A total of 7 marker genes for OSU-2S treatment of NSCLC were obtained. <i>AURKA</i> and <i>S1PR1</i> were screened as hub genes. Significant differences in the expression of <i>AURKA</i> and <i>S1PR1</i> between normal and lung adenocarcinoma (LUAD) tissues were found in the GEPIA2 database; Western blot showed that OSU-2S could affect <i>p-AURKA</i> and <i>S1PR1</i> protein expression. OSU-2S significantly inhibited tumour growth in A549 cells and xenografted animal models. (4) Conclusions: Our study confirms the inhibitory effect of OSU-2S on NSCLC, screens and demonstrates its potential targets <i>AURKA</i>(<i>p-AURKA</i>) and <i>S1PR1</i>, and provides a research basis for treating NSCLC with OSU-2S.

Item Description

10.3390/ph17050582
1424-8247